Zacks Investment Research
04 Nov 2026, 13:50 UTC · 22m ago
CVS Health (CVS) Beats Q3 Earnings and Revenue Estimates
Impact · against what's priced in
CVS's Q3 earnings and revenue beat are largely non-catalytic as the current price already incorporates the company's raised 2026 guidance and its recent pattern of beating estimates. The results confirm existing expectations for top-line growth and execution, but do not provide the sustained margin expansion evidence required to trigger a valuation re-rating.
- CVS+0.10
Already priced in
- The price assumes
The near-term beat-and-raise pattern from Q1 and Q2 2026
The Q3 adjusted EPS of $2.09 and revenue of $108.4 billion continue a four-quarter streak of beating consensus estimates, which the market has already factored into the current valuation.
What CVS's price assumes · Sep 9
